TEZSPIRE

PeakmAb

tezepelumab-ekko

AstraZeneca

BLASUBCUTANEOUSSOLUTIONPriority Review

Approved

Dec 2021

Lifecycle

Peak

Competitive Pressure

30/100

Clinical Trials

Mechanism of Action

Thymic Stromal Lymphopoietin Blockers

Pharmacologic Class:

Thymic Stromal Lymphopoietin Blocker

Clinical Trials (5)

NCT06998095N/ANot Yet Recruiting

Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea

Started Nov 2026

210 enrolled

Severe Asthma

NCT07302516Phase 3Not Yet Recruiting

Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma

Started Dec 2025

636 enrolled

Asthma

NCT07327697Phase 1Not Yet Recruiting

A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects

Started Dec 2025

178 enrolled

Healthy Participants

NCT06951867N/ARecruiting

Tezspire Cardiac Events PASS

Started Sep 2025

16,640 enrolled

Cardiovascular EventsMACE

NCT05729711N/AActive Not Recruiting

TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

Started Apr 2023

416 enrolled

Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)

Company

AstraZeneca

CAMBRIDGE, United Kingdom

1516 open jobs

External Resources

DailyMed

Full prescribing information

FDA Drugs@FDA

FDA approval history

RxNorm

Drug nomenclature & identifiers

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.